Furthermore, ADD3 has been associated with temozolomide (TMZ) resistance (Poon et al, 2015), glioma progression (Rani et al, 2013; van den Boom et al, 2003), and reduced glioma cell motility (Mariani et al, 2001). This evidence concerns the gene ADD3 and central nervous system cancer.